65 related articles for article (PubMed ID: 22623160)
1. Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Cosenza M; Civallero M; Grisendi G; Marcheselli L; Roat E; Bari A; Sacchi S
Ann Hematol; 2012 Oct; 91(10):1613-22. PubMed ID: 22623160
[TBL] [Abstract][Full Text] [Related]
2. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
[TBL] [Abstract][Full Text] [Related]
3. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
Civallero M; Cosenza M; Grisendi G; Marcheselli L; Todoerti K; Sacchi S
Leuk Lymphoma; 2010 Apr; 51(4):671-9. PubMed ID: 20218811
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Bodo J; Sedlak J; Maciejewski JP; Almasan A; Hsi ED
Apoptosis; 2011 Sep; 16(9):914-23. PubMed ID: 21667043
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Ruan J; Shah B; Martin P; Schuster SJ
Ann Oncol; 2016 Jul; 27(7):1226-34. PubMed ID: 27052651
[TBL] [Abstract][Full Text] [Related]
6. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Civallero M; Cosenza M; Bari A; Sacchi S
Expert Opin Investig Drugs; 2011 Aug; 20(8):1029-31. PubMed ID: 21702717
[No Abstract] [Full Text] [Related]
7. The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.
Brosseau C; Colston K; Dalgleish AG; Galustian C
Apoptosis; 2012 Feb; 17(2):164-73. PubMed ID: 22109882
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG; Fowler N; Morschhauser F
J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin.
Ma S; Rosen ST
Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
16. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
Visco C; Castegnaro S; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
Blood Cells Mol Dis; 2012 Jan; 48(1):68-75. PubMed ID: 22036761
[TBL] [Abstract][Full Text] [Related]
17. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Dueck G; Chua N; Prasad A; Finch D; Stewart D; White D; van der Jagt R; Johnston J; Belch A; Reiman T
Cancer; 2010 Oct; 116(19):4541-8. PubMed ID: 20572046
[TBL] [Abstract][Full Text] [Related]
18. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
